CanSino’s Covid-19 vaccine produces mixed results, early data suggest
Early data from CanSino Biologics’ Covid-19 vaccine trial are out, and some experts have expressed concerns about the potential effectiveness of the developmental candidate. The Phase 1 data from the study, published in the Lancet last Friday, showed that while CanSino’s vaccine — dubbed Ad5-nCoV — induced a moderate immune response in some individuals, the response elicited in half of the volunteers was underwhelming.
Part of the issue could be the vaccine itself, which is vector-based. It uses a weakened version of a cold virus, adenovirus 5, to introduce the genetic material of SARS-CoV-2 to the immune system.
As STAT’s Helen Branswell reports, up to 70% or more people in the population may already have preexisting immunity toward the Ad5 part of the vaccine from previous viral infections, which undermines the vaccine’s ability to trigger an immune response toward SARS-CoV-2 instead.
More data from the ongoing trial in Wuhan will be needed to determine what level of immune response will be enough to confer protection, as well as how long the protection will last.
The Chinese vaccine developer will also be launching a trial in Canada after getting permission last week, securing access to more patients after cases in China have subsided.
Read more.
Part of the issue could be the vaccine itself, which is vector-based. It uses a weakened version of a cold virus, adenovirus 5, to introduce the genetic material of SARS-CoV-2 to the immune system.
As STAT’s Helen Branswell reports, up to 70% or more people in the population may already have preexisting immunity toward the Ad5 part of the vaccine from previous viral infections, which undermines the vaccine’s ability to trigger an immune response toward SARS-CoV-2 instead.
More data from the ongoing trial in Wuhan will be needed to determine what level of immune response will be enough to confer protection, as well as how long the protection will last.
The Chinese vaccine developer will also be launching a trial in Canada after getting permission last week, securing access to more patients after cases in China have subsided.
Read more.
.png)
No hay comentarios:
Publicar un comentario